OA11084A - 2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines - Google Patents

2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines Download PDF

Info

Publication number: OA11084A
Authority: OA; OAPI
Prior art keywords: alkyl; formula; nmr; disease; nitrogen
Prior art date: 1997-02-10

Application number

OA9900173A

Other languages

English (en)

Inventor

John Adams Lowe Iii

Jolanta Nowakowski

Robert Alfred Volkmann

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-10

Filing date

1999-08-06

Publication date

2002-03-15

1999-08-06 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2002-03-15 Publication of OA11084A publication Critical patent/OA11084A/en

Links

150000001875 compounds Chemical class 0.000 claims abstract description 167
102000008299 Nitric Oxide Synthase Human genes 0.000 claims abstract description 26
108010021487 Nitric Oxide Synthase Proteins 0.000 claims abstract description 26
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 56
125000000217 alkyl group Chemical group 0.000 claims description 46
-1 nitro, hydroxy, cyano, amino Chemical group 0.000 claims description 37
238000000034 method Methods 0.000 claims description 32
229910052757 nitrogen Inorganic materials 0.000 claims description 31
125000001424 substituent group Chemical group 0.000 claims description 23
239000001257 hydrogen Substances 0.000 claims description 21
229910052739 hydrogen Inorganic materials 0.000 claims description 21
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
241000124008 Mammalia Species 0.000 claims description 19
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 19
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 16
208000002193 Pain Diseases 0.000 claims description 16
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 16
230000001154 acute effect Effects 0.000 claims description 16
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 16
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 16
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 16
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 15
125000005843 halogen group Chemical group 0.000 claims description 11
230000002401 inhibitory effect Effects 0.000 claims description 11
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
206010040070 Septic Shock Diseases 0.000 claims description 10
125000003545 alkoxy group Chemical group 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
206010028980 Neoplasm Diseases 0.000 claims description 9
HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 9
201000011510 cancer Diseases 0.000 claims description 9
208000027866 inflammatory disease Diseases 0.000 claims description 9
229920006395 saturated elastomer Polymers 0.000 claims description 9
230000036303 septic shock Effects 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
208000019901 Anxiety disease Diseases 0.000 claims description 8
208000000094 Chronic Pain Diseases 0.000 claims description 8
206010009900 Colitis ulcerative Diseases 0.000 claims description 8
206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 8
208000011231 Crohn disease Diseases 0.000 claims description 8
206010012289 Dementia Diseases 0.000 claims description 8
206010012335 Dependence Diseases 0.000 claims description 8
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 8
201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 8
208000010412 Glaucoma Diseases 0.000 claims description 8
206010019196 Head injury Diseases 0.000 claims description 8
208000023105 Huntington disease Diseases 0.000 claims description 8
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 8
208000019695 Migraine disease Diseases 0.000 claims description 8
208000028017 Psychotic disease Diseases 0.000 claims description 8
206010063837 Reperfusion injury Diseases 0.000 claims description 8
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims description 8
206010044541 Traumatic shock Diseases 0.000 claims description 8
201000006704 Ulcerative Colitis Diseases 0.000 claims description 8
206010047700 Vomiting Diseases 0.000 claims description 8
230000036506 anxiety Effects 0.000 claims description 8
206010015037 epilepsy Diseases 0.000 claims description 8
208000002780 macular degeneration Diseases 0.000 claims description 8
206010027599 migraine Diseases 0.000 claims description 8
229960005181 morphine Drugs 0.000 claims description 8
201000006417 multiple sclerosis Diseases 0.000 claims description 8
230000004770 neurodegeneration Effects 0.000 claims description 8
208000015122 neurodegenerative disease Diseases 0.000 claims description 8
201000008482 osteoarthritis Diseases 0.000 claims description 8
230000016087 ovulation Effects 0.000 claims description 8
206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
208000020431 spinal cord injury Diseases 0.000 claims description 8
208000018737 Parkinson disease Diseases 0.000 claims description 7
208000006011 Stroke Diseases 0.000 claims description 7
208000005298 acute pain Diseases 0.000 claims description 7
125000004122 cyclic group Chemical group 0.000 claims description 7
229910052760 oxygen Inorganic materials 0.000 claims description 7
230000035939 shock Effects 0.000 claims description 7
208000030507 AIDS Diseases 0.000 claims description 6
208000024827 Alzheimer disease Diseases 0.000 claims description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
125000003282 alkyl amino group Chemical group 0.000 claims description 6
125000003710 aryl alkyl group Chemical group 0.000 claims description 6
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 6
210000002569 neuron Anatomy 0.000 claims description 6
125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
239000001301 oxygen Substances 0.000 claims description 6
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 claims description 6
230000001988 toxicity Effects 0.000 claims description 6
231100000419 toxicity Toxicity 0.000 claims description 6
125000004429 atom Chemical group 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
125000001153 fluoro group Chemical group F* 0.000 claims description 5
150000002431 hydrogen Chemical class 0.000 claims description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
208000033679 diabetic kidney disease Diseases 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000001624 naphthyl group Chemical group 0.000 claims description 3
125000004430 oxygen atom Chemical group O* 0.000 claims description 3
125000006678 phenoxycarbonyl group Chemical group 0.000 claims description 3
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 3
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 3
JAKNYTQAGPEFJB-UHFFFAOYSA-N piperidin-2-amine Chemical group NC1CCCCN1 JAKNYTQAGPEFJB-UHFFFAOYSA-N 0.000 claims description 3
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
101100258328 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crc-2 gene Proteins 0.000 claims description 2
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 2
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
125000004432 carbon atom Chemical group C* 0.000 claims 2
125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 claims 1
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
229940125810 compound 20 Drugs 0.000 claims 1
108010041382 compound 20 Proteins 0.000 claims 1
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
125000003386 piperidinyl group Chemical group 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
239000003112 inhibitor Substances 0.000 abstract description 5
230000000694 effects Effects 0.000 abstract description 4
210000003169 central nervous system Anatomy 0.000 abstract description 2
230000002265 prevention Effects 0.000 abstract 1
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 137
238000005160 1H NMR spectroscopy Methods 0.000 description 111
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 57
238000006243 chemical reaction Methods 0.000 description 48
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 47
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 45
229940093499 ethyl acetate Drugs 0.000 description 45
235000019439 ethyl acetate Nutrition 0.000 description 44
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 43
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
238000010992 reflux Methods 0.000 description 36
229910001868 water Inorganic materials 0.000 description 36
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 33
239000000243 solution Substances 0.000 description 32
239000011541 reaction mixture Substances 0.000 description 31
239000007787 solid Substances 0.000 description 31
238000005481 NMR spectroscopy Methods 0.000 description 29
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
239000000203 mixture Substances 0.000 description 25
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 24
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 23
239000012043 crude product Substances 0.000 description 23
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 21
229960003010 sodium sulfate Drugs 0.000 description 21
229910052938 sodium sulfate Inorganic materials 0.000 description 21
235000011152 sodium sulphate Nutrition 0.000 description 21
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
239000012267 brine Substances 0.000 description 19
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 19
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 17
239000000284 extract Substances 0.000 description 15
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 14
238000003756 stirring Methods 0.000 description 14
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
239000002253 acid Substances 0.000 description 13
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 12
239000010410 layer Substances 0.000 description 12
239000003921 oil Substances 0.000 description 12
235000019198 oils Nutrition 0.000 description 12
HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 11
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 11
235000011121 sodium hydroxide Nutrition 0.000 description 11
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 10
229940035423 ethyl ether Drugs 0.000 description 10
229910000027 potassium carbonate Inorganic materials 0.000 description 10
150000003839 salts Chemical class 0.000 description 10
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 9
229940093956 potassium carbonate Drugs 0.000 description 9
235000011181 potassium carbonates Nutrition 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
239000012044 organic layer Substances 0.000 description 8
102100022397 Nitric oxide synthase, brain Human genes 0.000 description 7
101710111444 Nitric oxide synthase, brain Proteins 0.000 description 7
AEKQCMMJOMDJPC-UHFFFAOYSA-N 2-bromo-6-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=CC(Br)=N1 AEKQCMMJOMDJPC-UHFFFAOYSA-N 0.000 description 6
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 6
239000003814 drug Substances 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
229910000029 sodium carbonate Inorganic materials 0.000 description 6
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
238000005804 alkylation reaction Methods 0.000 description 5
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
239000012280 lithium aluminium hydride Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 5
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
201000004624 Dermatitis Diseases 0.000 description 4
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
201000004681 Psoriasis Diseases 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
230000029936 alkylation Effects 0.000 description 4
VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 4
206010003246 arthritis Diseases 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
208000010668 atopic eczema Diseases 0.000 description 4
239000002585 base Substances 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
238000009835 boiling Methods 0.000 description 4
UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000706 filtrate Substances 0.000 description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
229940083608 sodium hydroxide Drugs 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
HVWZMGZBJCJDOX-UHFFFAOYSA-N 1-bromo-3-phenylmethoxybenzene Chemical compound BrC1=CC=CC(OCC=2C=CC=CC=2)=C1 HVWZMGZBJCJDOX-UHFFFAOYSA-N 0.000 description 3
LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 3
GVUCVRXLDWFFPO-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclopropylphenol Chemical compound NC1=CC=CC(C=2C(=CC(O)=CC=2)C2CC2)=N1 GVUCVRXLDWFFPO-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
102000004127 Cytokines Human genes 0.000 description 3
108090000695 Cytokines Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
150000003927 aminopyridines Chemical class 0.000 description 3
125000001246 bromo group Chemical group Br* 0.000 description 3
229910000024 caesium carbonate Inorganic materials 0.000 description 3
239000003638 chemical reducing agent Substances 0.000 description 3
125000001309 chloro group Chemical group Cl* 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
150000004678 hydrides Chemical class 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
125000002346 iodo group Chemical group I* 0.000 description 3
229910052943 magnesium sulfate Inorganic materials 0.000 description 3
235000019341 magnesium sulphate Nutrition 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
229910052763 palladium Inorganic materials 0.000 description 3
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
238000001953 recrystallisation Methods 0.000 description 3
KWQRKOSMSFLBTJ-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-UHFFFAOYSA-N 0.000 description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
PCQJZQFJTUYDOI-UHFFFAOYSA-N (2-cyclopentyl-4-phenylmethoxyphenyl)boronic acid Chemical compound C1=C(C2CCCC2)C(B(O)O)=CC=C1OCC1=CC=CC=C1 PCQJZQFJTUYDOI-UHFFFAOYSA-N 0.000 description 2
JACGHVGDEQRIFL-UHFFFAOYSA-N (4-fluoro-2,3-dimethylphenyl)boronic acid Chemical compound CC1=C(C)C(B(O)O)=CC=C1F JACGHVGDEQRIFL-UHFFFAOYSA-N 0.000 description 2
BPMLPIWGDJTUNN-UHFFFAOYSA-N (4-phenylmethoxy-2-propan-2-ylphenyl)boronic acid Chemical compound C1=C(B(O)O)C(C(C)C)=CC(OCC=2C=CC=CC=2)=C1 BPMLPIWGDJTUNN-UHFFFAOYSA-N 0.000 description 2
RMGFLMXDCGQKPS-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine Chemical compound ClCCN1CCCC1 RMGFLMXDCGQKPS-UHFFFAOYSA-N 0.000 description 2
NFPIQVUUOIIMDF-UHFFFAOYSA-N 1-(3-phenylmethoxyphenyl)cyclopentan-1-ol Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C1(O)CCCC1 NFPIQVUUOIIMDF-UHFFFAOYSA-N 0.000 description 2
OYWLDZXWISLBMC-UHFFFAOYSA-N 1-bromo-4-fluoro-2,3-dimethylbenzene Chemical group CC1=C(C)C(Br)=CC=C1F OYWLDZXWISLBMC-UHFFFAOYSA-N 0.000 description 2
UWGVYABJZODXCG-UHFFFAOYSA-N 1-cyclopentyl-3-phenylmethoxybenzene Chemical compound C=1C=CC=CC=1COC(C=1)=CC=CC=1C1CCCC1 UWGVYABJZODXCG-UHFFFAOYSA-N 0.000 description 2
IRHHHUXUGRCHRE-UHFFFAOYSA-N 2-(2-cyclopropyl-4-phenylmethoxyphenyl)-6-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=CC(C=2C(=CC(OCC=3C=CC=CC=3)=CC=2)C2CC2)=N1 IRHHHUXUGRCHRE-UHFFFAOYSA-N 0.000 description 2
WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 2
KGAOBXXXNFRSSW-UHFFFAOYSA-N 3-cyclobutylphenol Chemical compound OC1=CC=CC(C2CCC2)=C1 KGAOBXXXNFRSSW-UHFFFAOYSA-N 0.000 description 2
VLJSLTNSFSOYQR-UHFFFAOYSA-N 3-propan-2-ylphenol Chemical compound CC(C)C1=CC=CC(O)=C1 VLJSLTNSFSOYQR-UHFFFAOYSA-N 0.000 description 2
KMPIDOMSSJIINY-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclobutylphenol Chemical compound NC1=CC=CC(C=2C(=CC(O)=CC=2)C2CCC2)=N1 KMPIDOMSSJIINY-UHFFFAOYSA-N 0.000 description 2
NWBNXZXGFIIUIP-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-cyclopentylphenol Chemical compound NC1=CC=CC(C=2C(=CC(O)=CC=2)C2CCCC2)=N1 NWBNXZXGFIIUIP-UHFFFAOYSA-N 0.000 description 2
FHIRTCZQNMPCJR-UHFFFAOYSA-N 4-bromo-2-ethoxyphenol Chemical compound CCOC1=CC(Br)=CC=C1O FHIRTCZQNMPCJR-UHFFFAOYSA-N 0.000 description 2
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000001953 Hypotension Diseases 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
102000000588 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229910017912 NH2OH Inorganic materials 0.000 description 2
108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241000700159 Rattus Species 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000003513 alkali Substances 0.000 description 2
150000004703 alkoxides Chemical class 0.000 description 2
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
229960001040 ammonium chloride Drugs 0.000 description 2
235000019270 ammonium chloride Nutrition 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
229910000085 borane Inorganic materials 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
229910052794 bromium Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
229960004132 diethyl ether Drugs 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
230000036543 hypotension Effects 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000007788 liquid Substances 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
229960003753 nitric oxide Drugs 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
230000007170 pathology Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000376 reactant Substances 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
UOUFRTFWWBCVPV-UHFFFAOYSA-N tert-butyl 4-(2,4-dioxo-1H-thieno[3,2-d]pyrimidin-3-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CC1)n1c(=O)[nH]c2ccsc2c1=O UOUFRTFWWBCVPV-UHFFFAOYSA-N 0.000 description 2
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
GOGJRPAACJJGIW-UHFFFAOYSA-N (2-cyclobutyl-4-phenylmethoxyphenyl)boronic acid Chemical compound C1=C(C2CCC2)C(B(O)O)=CC=C1OCC1=CC=CC=C1 GOGJRPAACJJGIW-UHFFFAOYSA-N 0.000 description 1
OCRDUFMMMZJZQV-UHFFFAOYSA-N (2-methoxy-4-phenylmethoxyphenyl)boronic acid Chemical compound C1=C(B(O)O)C(OC)=CC(OCC=2C=CC=CC=2)=C1 OCRDUFMMMZJZQV-UHFFFAOYSA-N 0.000 description 1
LIIDHYIODBKDJM-UHFFFAOYSA-N (4-bromo-3-methoxyphenyl) 4-methylbenzenesulfonate Chemical compound C1=C(Br)C(OC)=CC(OS(=O)(=O)C=2C=CC(C)=CC=2)=C1 LIIDHYIODBKDJM-UHFFFAOYSA-N 0.000 description 1
UCRRVHJLSNXDID-UHFFFAOYSA-N 1-(3-phenylmethoxyphenyl)cyclobutan-1-ol Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C1(O)CCC1 UCRRVHJLSNXDID-UHFFFAOYSA-N 0.000 description 1
WTXVEGQWZKNRHO-UHFFFAOYSA-N 1-bromo-2-cyclobutyl-4-phenylmethoxybenzene Chemical compound C1=C(C2CCC2)C(Br)=CC=C1OCC1=CC=CC=C1 WTXVEGQWZKNRHO-UHFFFAOYSA-N 0.000 description 1
DOHBDYZGYOJXOA-UHFFFAOYSA-N 1-bromo-2-cyclopentyl-4-phenylmethoxybenzene Chemical compound C1=C(C2CCCC2)C(Br)=CC=C1OCC1=CC=CC=C1 DOHBDYZGYOJXOA-UHFFFAOYSA-N 0.000 description 1
NRBNIWDPEXOOBW-UHFFFAOYSA-N 1-bromo-2-cyclopropyl-4-phenylmethoxybenzene Chemical compound C1=C(C2CC2)C(Br)=CC=C1OCC1=CC=CC=C1 NRBNIWDPEXOOBW-UHFFFAOYSA-N 0.000 description 1
XNIVMZIZMUITKK-UHFFFAOYSA-N 1-bromo-2-methoxy-4-phenylmethoxybenzene Chemical compound C1=C(Br)C(OC)=CC(OCC=2C=CC=CC=2)=C1 XNIVMZIZMUITKK-UHFFFAOYSA-N 0.000 description 1
WGFWXWLRSHVXAE-UHFFFAOYSA-N 1-bromo-4-phenylmethoxy-2-propan-2-ylbenzene Chemical compound C1=C(Br)C(C(C)C)=CC(OCC=2C=CC=CC=2)=C1 WGFWXWLRSHVXAE-UHFFFAOYSA-N 0.000 description 1
JTWUTHFFXFUCGM-UHFFFAOYSA-N 1-cyclobutyl-3-phenylmethoxybenzene Chemical compound C=1C=CC=CC=1COC(C=1)=CC=CC=1C1CCC1 JTWUTHFFXFUCGM-UHFFFAOYSA-N 0.000 description 1
RSGJXCRPBQHQLR-UHFFFAOYSA-N 1-cyclopropyl-3-phenylmethoxybenzene Chemical compound C=1C=CC=CC=1COC(C=1)=CC=CC=1C1CC1 RSGJXCRPBQHQLR-UHFFFAOYSA-N 0.000 description 1
AWLDSXJCQWTJPC-UHFFFAOYSA-N 1-fluoro-2,3-dimethylbenzene Chemical group CC1=CC=CC(F)=C1C AWLDSXJCQWTJPC-UHFFFAOYSA-N 0.000 description 1
BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
BYOORBPQVHIOKM-UHFFFAOYSA-N 2-(2,5-dimethyl-1h-pyrrol-3-yl)-6-(4-fluoro-2,3-dimethylphenyl)pyridine Chemical compound N1C(C)=CC(C=2N=C(C=CC=2)C=2C(=C(C)C(F)=CC=2)C)=C1C BYOORBPQVHIOKM-UHFFFAOYSA-N 0.000 description 1
XHTQIXYZTFXJQS-UHFFFAOYSA-N 2-(2,5-dimethylpyrrol-1-yl)-6-(2-methoxy-4-phenylmethoxyphenyl)pyridine Chemical compound C=1C=C(C=2N=C(C=CC=2)N2C(=CC=C2C)C)C(OC)=CC=1OCC1=CC=CC=C1 XHTQIXYZTFXJQS-UHFFFAOYSA-N 0.000 description 1
XGGJPOFXBCURIT-UHFFFAOYSA-N 2-(2,5-dimethylpyrrol-1-yl)-6-(4-phenylmethoxy-2-propan-2-ylphenyl)pyridine Chemical compound C=1C=C(C=2N=C(C=CC=2)N2C(=CC=C2C)C)C(C(C)C)=CC=1OCC1=CC=CC=C1 XGGJPOFXBCURIT-UHFFFAOYSA-N 0.000 description 1
TZOCQGHBDUCQNK-UHFFFAOYSA-N 2-(2-cyclobutyl-4-phenylmethoxyphenyl)-6-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=CC(C=2C(=CC(OCC=3C=CC=CC=3)=CC=2)C2CCC2)=N1 TZOCQGHBDUCQNK-UHFFFAOYSA-N 0.000 description 1
OGGMQNTWQQMVST-UHFFFAOYSA-N 2-[4-(6-aminopyridin-2-yl)-3,5-dimethylphenoxy]acetamide Chemical compound CC1=CC(OCC(N)=O)=CC(C)=C1C1=CC=CC(N)=N1 OGGMQNTWQQMVST-UHFFFAOYSA-N 0.000 description 1
SQWPRPIVUJCCHY-UHFFFAOYSA-N 2-bromo-6-(2,5-dimethyl-1h-pyrrol-3-yl)pyridine Chemical compound N1C(C)=CC(C=2N=C(Br)C=CC=2)=C1C SQWPRPIVUJCCHY-UHFFFAOYSA-N 0.000 description 1
SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
NZJMQFDGADIRLV-UHFFFAOYSA-N 3-cyclopentylphenol Chemical compound OC1=CC=CC(C2CCCC2)=C1 NZJMQFDGADIRLV-UHFFFAOYSA-N 0.000 description 1
UGCUXDWHQYJKMK-UHFFFAOYSA-N 3-cyclopropyl-4-[6-(2,5-dimethylpyrrol-1-yl)pyridin-2-yl]phenol Chemical compound CC1=CC=C(C)N1C1=CC=CC(C=2C(=CC(O)=CC=2)C2CC2)=N1 UGCUXDWHQYJKMK-UHFFFAOYSA-N 0.000 description 1
125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
FWXKPCHUSMDKJD-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-3-methoxyphenol Chemical compound COC1=CC(O)=CC=C1C1=CC=CC(N)=N1 FWXKPCHUSMDKJD-UHFFFAOYSA-N 0.000 description 1
RHVZNUMCGSLHME-UHFFFAOYSA-N 4-(6-aminopyridin-2-yl)-5-methoxy-2-propylphenol Chemical compound C1=C(O)C(CCC)=CC(C=2N=C(N)C=CC=2)=C1OC RHVZNUMCGSLHME-UHFFFAOYSA-N 0.000 description 1
WHSIIJQOEGXWSN-UHFFFAOYSA-N 4-bromo-2-methoxyphenol Chemical compound COC1=CC(Br)=CC=C1O WHSIIJQOEGXWSN-UHFFFAOYSA-N 0.000 description 1
UYDZUCNMZXCLJI-UHFFFAOYSA-N 4-bromo-3-methoxyphenol Chemical compound COC1=CC(O)=CC=C1Br UYDZUCNMZXCLJI-UHFFFAOYSA-N 0.000 description 1
MPCCNXGZCOXPMG-UHFFFAOYSA-N 4-bromobenzene-1,3-diol Chemical compound OC1=CC=C(Br)C(O)=C1 MPCCNXGZCOXPMG-UHFFFAOYSA-N 0.000 description 1
QPCPIBGPAYBODR-UHFFFAOYSA-N 6-[2-methoxy-4-(1-methylazetidin-3-yl)oxyphenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CN(C)C1 QPCPIBGPAYBODR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
CMCVDHBBWOUHOU-UHFFFAOYSA-N Cc1cc(OCc2ccccc2)cc(C)c1B(O)O Chemical compound Cc1cc(OCc2ccccc2)cc(C)c1B(O)O CMCVDHBBWOUHOU-UHFFFAOYSA-N 0.000 description 1
LXPOYZVSGGMEMK-UHFFFAOYSA-N Cc1cc(OCc2ccccc2)cc(C)c1Br Chemical compound Cc1cc(OCc2ccccc2)cc(C)c1Br LXPOYZVSGGMEMK-UHFFFAOYSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000400611 Eucalyptus deanei Species 0.000 description 1
208000009386 Experimental Arthritis Diseases 0.000 description 1
BYTJTXKQBSNGCL-UHFFFAOYSA-N Fc(cc(cc1)OCc2ccccc2)c1Br Chemical compound Fc(cc(cc1)OCc2ccccc2)c1Br BYTJTXKQBSNGCL-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
206010028851 Necrosis Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
PQWKGFALWCOVTC-UHFFFAOYSA-N OB(c(ccc(OCc1ccccc1)c1)c1F)O Chemical compound OB(c(ccc(OCc1ccccc1)c1)c1F)O PQWKGFALWCOVTC-UHFFFAOYSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010044248 Toxic shock syndrome Diseases 0.000 description 1
231100000650 Toxic shock syndrome Toxicity 0.000 description 1
102100029469 WD repeat and HMG-box DNA-binding protein 1 Human genes 0.000 description 1
101710097421 WD repeat and HMG-box DNA-binding protein 1 Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical compound [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
235000011114 ammonium hydroxide Nutrition 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003502 anti-nociceptive effect Effects 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
125000005604 azodicarboxylate group Chemical group 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
238000004040 coloring Methods 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
238000006880 cross-coupling reaction Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
ZBQUMMFUJLOTQC-UHFFFAOYSA-L dichloronickel;3-diphenylphosphanylpropyl(diphenyl)phosphane Chemical compound Cl[Ni]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 ZBQUMMFUJLOTQC-UHFFFAOYSA-L 0.000 description 1
229910001873 dinitrogen Inorganic materials 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
XBRDBODLCHKXHI-UHFFFAOYSA-N epolamine Chemical compound OCCN1CCCC1 XBRDBODLCHKXHI-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
229940052303 ethers for general anesthesia Drugs 0.000 description 1
CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000006138 lithiation reaction Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000008203 oral pharmaceutical composition Substances 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 1
239000006072 paste Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
HETDSEQVGCUOJR-UHFFFAOYSA-N phenyl 2-ethoxyacetate Chemical compound CCOCC(=O)OC1=CC=CC=C1 HETDSEQVGCUOJR-UHFFFAOYSA-N 0.000 description 1
RRGKOFFIQZTPRH-UHFFFAOYSA-N phenyl 2-methoxyacetate Chemical compound COCC(=O)OC1=CC=CC=C1 RRGKOFFIQZTPRH-UHFFFAOYSA-N 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000000171 quenching effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
APCBTRDHCDOPNY-SSDOTTSWSA-N tert-butyl (3r)-3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC[C@@H](O)C1 APCBTRDHCDOPNY-SSDOTTSWSA-N 0.000 description 1
HEZIRBUGQNXOTL-UHFFFAOYSA-N tert-butyl 3-[3-(6-aminopyridin-2-yl)-4-cyclobutylphenoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1OC(C=C1C=2N=C(N)C=CC=2)=CC=C1C1CCC1 HEZIRBUGQNXOTL-UHFFFAOYSA-N 0.000 description 1
BLSJIIWKQYIWHB-UHFFFAOYSA-N tert-butyl 3-[3-(6-aminopyridin-2-yl)-4-cyclopropylphenoxy]pyrrolidine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC1OC(C=C1C=2N=C(N)C=CC=2)=CC=C1C1CC1 BLSJIIWKQYIWHB-UHFFFAOYSA-N 0.000 description 1
COTGZLZEBQPQIT-UHFFFAOYSA-N tert-butyl 3-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]pyrrolidine-1-carboxylate Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CCN(C(=O)OC(C)(C)C)C1 COTGZLZEBQPQIT-UHFFFAOYSA-N 0.000 description 1
UFRRZPTVDODIPQ-UHFFFAOYSA-N tert-butyl 3-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]pyrrolidine-1-carboxylate;pyridin-2-amine Chemical compound NC1=CC=CC=N1.C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CCN(C(=O)OC(C)(C)C)C1 UFRRZPTVDODIPQ-UHFFFAOYSA-N 0.000 description 1
QOHGGWJARDFFLF-UHFFFAOYSA-N tert-butyl 4-[4-(6-aminopyridin-2-yl)-3-methoxyphenoxy]piperidine-1-carboxylate Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OC)=CC=1OC1CCN(C(=O)OC(C)(C)C)CC1 QOHGGWJARDFFLF-UHFFFAOYSA-N 0.000 description 1
MFEFCEANRZENEN-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate;methanesulfonic acid Chemical compound CS(O)(=O)=O.CC(C)(C)OC(=O)N1CCC(O)CC1 MFEFCEANRZENEN-UHFFFAOYSA-N 0.000 description 1
NHFVAONVLCETEV-UHFFFAOYSA-N tert-butyl 4-isoquinolin-5-ylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C1=CC=CC2=CN=CC=C12 NHFVAONVLCETEV-UHFFFAOYSA-N 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
FJGIHZCEZAZPSP-UHFFFAOYSA-N tetrahedrane Chemical compound C12C3C1C32 FJGIHZCEZAZPSP-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
ULSDMUVEXKOYBU-ZDUSSCGKSA-N zolmitriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1C[C@H]1COC(=O)N1 ULSDMUVEXKOYBU-ZDUSSCGKSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA9900173A 1997-02-10 1999-08-06 2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines OA11084A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US3753397P	1997-02-10	1997-02-10

Publications (1)

Publication Number	Publication Date
OA11084A true OA11084A (en)	2002-03-15

Family

ID=21894849

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900173A OA11084A (en)	1997-02-10	1999-08-06	2-Amino--6-(2-substituted-4-phenoxy)-substituted- pyridines

Country Status (44)

Country	Link
US (2)	US20010007873A1 (de)
EP (1)	EP0958282B1 (de)
JP (1)	JP3505189B2 (de)
KR (1)	KR100460399B1 (de)
CN (3)	CN1523015A (de)
AP (1)	AP833A (de)
AR (1)	AR011117A1 (de)
AT (1)	ATE271544T1 (de)
AU (1)	AU744313B2 (de)
BG (1)	BG103633A (de)
BR (1)	BR9811093A (de)
CA (1)	CA2277990C (de)
CO (1)	CO4920225A1 (de)
CZ (1)	CZ292135B6 (de)
DE (1)	DE69825147T2 (de)
DK (1)	DK0958282T3 (de)
DZ (1)	DZ2414A1 (de)
EA (1)	EA003834B1 (de)
ES (1)	ES2224354T3 (de)
GT (1)	GT199800032A (de)
HN (1)	HN1998000030A (de)
HR (1)	HRP980069A2 (de)
HU (1)	HUP0000762A3 (de)
IL (1)	IL130898A0 (de)
IS (1)	IS5118A (de)
MA (1)	MA27676A1 (de)
MY (1)	MY120976A (de)
NO (1)	NO314803B1 (de)
NZ (2)	NZ518345A (de)
OA (1)	OA11084A (de)
PA (1)	PA8446301A1 (de)
PE (1)	PE58599A1 (de)
PL (1)	PL335161A1 (de)
PT (1)	PT958282E (de)
SI (1)	SI0958282T1 (de)
SK (1)	SK101199A3 (de)
TN (1)	TNSN98024A1 (de)
TR (1)	TR199901917T2 (de)
TW (1)	TW458969B (de)
UA (1)	UA64740C2 (de)
UY (1)	UY24881A1 (de)
WO (1)	WO1998034919A1 (de)
YU (1)	YU35699A (de)
ZA (1)	ZA981017B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20010049379A1 (en)	1997-08-27	2001-12-06	Lowe John Adams	2-aminopyridines containing fused ring substituents
CN1303379A (zh) *	1998-06-03	2001-07-11	辉瑞产品公司	作为氧化氮合酶抑制剂的含稠环取代基的2－氨基吡啶
HUP0103113A3 (en) *	1998-08-11	2002-02-28	Pfizer Prod Inc	New pharmaceutical compositions uses for nos inhibitors
US7115557B2 (en)	1998-09-25	2006-10-03	Sciaticon Ab	Use of certain drugs for treating nerve root injury
SE9803710L (sv)	1998-09-25	2000-03-26	A & Science Invest Ab	Användning av vissa substanser för behandling av nervrotsskador
CA2364719C (en)	1999-02-25	2006-07-04	Pfizer Products Inc.	2-aminopyridines containing fused ring substituents
FR2812635B1 (fr) *	2000-08-01	2002-10-11	Aventis Pharma Sa	Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
GB0019006D0 (en) *	2000-08-04	2000-09-20	Astrazeneca Ab	Novel compounds
US20030232739A1 (en) *	2001-08-15	2003-12-18	Pfizer Inc.	Pharmaceutical combinations comprising a NOS inhibitor and an NMDA receptor antagonist
US20030045449A1 (en) *	2001-08-15	2003-03-06	Pfizer, Inc.	Pharmaceutical combinations for the treatment of neurodegenerative diseases
US6803470B2 (en)	2001-10-10	2004-10-12	Pfizer Inc	2-amino-6-(2,4,5-substituted-phenyl)-pyridines
DOP2002000467A (es) *	2001-10-10	2003-04-15	Pfizer Prod Inc	2-amino-6 (fenilo sustituido en las posiciones 2,4,5)-piridinas
US7045652B2 (en)	2002-07-03	2006-05-16	Pfizer Inc	Processes for preparing substituted aryl boronic acids
US20040092741A1 (en) *	2002-11-08	2004-05-13	Pfizer Inc	Substituted pyridines via boronic acid coupling
WO2005007627A1 (ja) *	2003-07-18	2005-01-27	Nihon Nohyaku Co., Ltd.	フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
US20080070952A1 (en) *	2005-02-21	2008-03-20	Proximagen Ltd.,	Inhibition or Treatment of Dyskinesia
GB0607196D0 (en) *	2006-04-11	2006-05-17	Prosidion Ltd	G-protein coupled receptor agonists
WO2008080938A1 (en) *	2006-12-28	2008-07-10	Basf Se	Use 2-substituted pyridines for cancer treatment
UA105182C2 (ru)	2008-07-03	2014-04-25	Ньюрексон, Інк.	Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
AU2014221489B2 (en)	2013-02-28	2018-03-08	Tiumbio Co., Ltd.	Tricyclic compound and use thereof
EP3066072B1 (de) *	2013-11-07	2021-11-03	The University of Kansas	Biphenylamidderivate als hsp90-inhibitoren
WO2016024602A1 (ja) *	2014-08-13	2016-02-18	ＭｅｉｊｉＳｅｉｋａファルマ株式会社	結晶性抗白癬菌薬およびその製造方法
CN106265640B (zh) *	2016-08-11	2019-05-14	吉林大学	Appa在制备治疗糖尿病肾病药物中的应用
CN108069831B (zh) *	2018-01-25	2020-11-24	上海恩氟佳科技有限公司	一种合成2,3-二甲基-4-氟苯酚的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0674627A1 (de) *	1992-12-18	1995-10-04	The Wellcome Foundation Limited	Pyrimidin-, pyridin-, pteridinon- und indazolderivate als enzyminhibitoren
AU688811B2 (en) *	1993-10-21	1998-03-19	G.D. Searle & Co.	Amidino derivatives useful as nitric oxide synthase inhibitors
AU4515696A (en) *	1994-12-12	1996-07-03	Merck & Co., Inc.	Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
NZ326874A (en) *	1996-03-29	2000-01-28	Pfizer	6-phenylpyridyl-2-amine derivatives

1998
- 1998-01-29 DK DK98900635T patent/DK0958282T3/da active
- 1998-01-29 PT PT98900635T patent/PT958282E/pt unknown
- 1998-01-29 HU HU0000762A patent/HUP0000762A3/hu unknown
- 1998-01-29 WO PCT/IB1998/000112 patent/WO1998034919A1/en not_active Ceased
- 1998-01-29 UA UA99084543A patent/UA64740C2/uk unknown
- 1998-01-29 PL PL98335161A patent/PL335161A1/xx unknown
- 1998-01-29 KR KR10-1999-7007065A patent/KR100460399B1/ko not_active Expired - Fee Related
- 1998-01-29 DE DE69825147T patent/DE69825147T2/de not_active Expired - Fee Related
- 1998-01-29 CN CNA2004100073282A patent/CN1523015A/zh active Pending
- 1998-01-29 NZ NZ518345A patent/NZ518345A/en unknown
- 1998-01-29 SI SI9830699T patent/SI0958282T1/xx unknown
- 1998-01-29 AT AT98900635T patent/ATE271544T1/de not_active IP Right Cessation
- 1998-01-29 CN CNA031086047A patent/CN1515554A/zh active Pending
- 1998-01-29 AU AU55727/98A patent/AU744313B2/en not_active Ceased
- 1998-01-29 EP EP98900635A patent/EP0958282B1/de not_active Expired - Lifetime
- 1998-01-29 IL IL13089898A patent/IL130898A0/xx unknown
- 1998-01-29 CN CN98802392A patent/CN1246848A/zh active Pending
- 1998-01-29 ES ES98900635T patent/ES2224354T3/es not_active Expired - Lifetime
- 1998-01-29 NZ NZ336623A patent/NZ336623A/xx unknown
- 1998-01-29 JP JP53404898A patent/JP3505189B2/ja not_active Expired - Fee Related
- 1998-01-29 CA CA002277990A patent/CA2277990C/en not_active Expired - Fee Related
- 1998-01-29 EA EA199900632A patent/EA003834B1/ru not_active IP Right Cessation
- 1998-01-29 CZ CZ19992769A patent/CZ292135B6/cs not_active IP Right Cessation
- 1998-01-29 TR TR1999/01917T patent/TR199901917T2/xx unknown
- 1998-01-29 SK SK1011-99A patent/SK101199A3/sk unknown
- 1998-01-29 YU YU35699A patent/YU35699A/sh unknown
- 1998-01-29 BR BR9811093-4A patent/BR9811093A/pt not_active Application Discontinuation
- 1998-02-03 TW TW087101311A patent/TW458969B/zh not_active IP Right Cessation
- 1998-02-05 AP APAP/P/1998/001178A patent/AP833A/en active
- 1998-02-05 PE PE1998000082A patent/PE58599A1/es not_active Application Discontinuation
- 1998-02-06 MY MYPI98000488A patent/MY120976A/en unknown
- 1998-02-06 UY UY24881A patent/UY24881A1/es not_active Application Discontinuation
- 1998-02-09 DZ DZ980024A patent/DZ2414A1/xx active
- 1998-02-09 TN TNTNSN98024A patent/TNSN98024A1/fr unknown
- 1998-02-09 AR ARP980100551A patent/AR011117A1/es not_active Application Discontinuation
- 1998-02-09 ZA ZA9801017A patent/ZA981017B/xx unknown
- 1998-02-09 MA MA24958A patent/MA27676A1/fr unknown
- 1998-02-09 HN HN1998000030A patent/HN1998000030A/es unknown
- 1998-02-10 CO CO98006875A patent/CO4920225A1/es unknown
- 1998-02-10 HR HR60/037,533A patent/HRP980069A2/hr not_active Application Discontinuation
- 1998-02-10 PA PA19988446301A patent/PA8446301A1/es unknown
- 1998-02-11 GT GT199800032A patent/GT199800032A/es unknown
- 1998-07-31 US US09/127,158 patent/US20010007873A1/en not_active Abandoned
1999
- 1999-07-16 IS IS5118A patent/IS5118A/is unknown
- 1999-08-03 BG BG103633A patent/BG103633A/bg unknown
- 1999-08-06 OA OA9900173A patent/OA11084A/en unknown
- 1999-08-09 NO NO19993823A patent/NO314803B1/no unknown
2003
- 2003-02-20 US US10/371,357 patent/US20030162765A1/en not_active Abandoned

Also Published As

Publication number	Publication date
SI0958282T1 (en)	2005-02-28
WO1998034919A1 (en)	1998-08-13
ATE271544T1 (de)	2004-08-15
GT199800032A (es)	1998-02-11
EP0958282A1 (de)	1999-11-24
CN1515554A (zh)	2004-07-28
CZ292135B6 (cs)	2003-08-13
PE58599A1 (es)	1999-06-12
ES2224354T3 (es)	2005-03-01
HUP0000762A3 (en)	2000-10-30
AR011117A1 (es)	2000-08-02
NO993823L (no)	1999-08-09
UA64740C2 (uk)	2004-03-15
TW458969B (en)	2001-10-11
US20030162765A1 (en)	2003-08-28
YU35699A (sh)	2002-06-19
HN1998000030A (es)	1998-10-22
KR100460399B1 (ko)	2004-12-08
IL130898A0 (en)	2001-01-28
BR9811093A (pt)	2000-07-18
CN1523015A (zh)	2004-08-25
CA2277990C (en)	2006-08-01
DE69825147D1 (de)	2004-08-26
TNSN98024A1 (fr)	2005-03-15
CO4920225A1 (es)	2000-05-29
UY24881A1 (es)	2000-12-29
PL335161A1 (en)	2000-04-10
MA27676A1 (fr)	2006-01-02
EA003834B1 (ru)	2003-10-30
DE69825147T2 (de)	2005-08-04
SK101199A3 (en)	2000-10-09
ZA981017B (en)	1999-08-10
AP833A (en)	2000-05-10
CZ276999A3 (cs)	2000-05-17
HUP0000762A2 (hu)	2000-09-28
KR20000070803A (ko)	2000-11-25
CA2277990A1 (en)	1998-08-13
HRP980069A2 (en)	1998-12-31
NO314803B1 (no)	2003-05-26
JP3505189B2 (ja)	2004-03-08
DK0958282T3 (da)	2004-11-29
NO993823D0 (no)	1999-08-09
JP2000509408A (ja)	2000-07-25
CN1246848A (zh)	2000-03-08
PT958282E (pt)	2004-11-30
PA8446301A1 (es)	2000-05-24
AU744313B2 (en)	2002-02-21
IS5118A (is)	1999-07-29
DZ2414A1 (fr)	2003-01-04
MY120976A (en)	2005-12-30
NZ518345A (en)	2005-02-25
US20010007873A1 (en)	2001-07-12
BG103633A (bg)	2000-11-30
EA199900632A1 (ru)	2000-02-28
TR199901917T2 (xx)	1999-12-21
EP0958282B1 (de)	2004-07-21
NZ336623A (en)	2000-11-24
AU5572798A (en)	1998-08-26

Publication	Publication Date	Title
AP833A (en)	2000-05-10	2-Amino-6-(2-substituted-4-phenoxy)-substituted-pyridines.
EP3658547B1 (de)	2023-08-16	Verfahren zur herstellung von n-(5-(4-(4-formyl-3-phenyl-1h-pyrazol-1-yl)pyrimidin-2-ylamino)-4-methoxy-2-morpholinophenyl)acrylamid
EP2315746A1 (de)	2011-05-04	Harnstoffderivate als antibakterielle mittel
EP0629189A1 (de)	1994-12-21	Verfahren zur herstellung von zwischenprodukten für die synthese von chinozin-antibiotika.
JP2022528919A (ja)	2022-06-16	Ｍａｌｔ１阻害剤としての尿素誘導体
EP2664617A1 (de)	2013-11-20	Verfahren zur Herstellung eines 2,6-Diaryl-Piperidinderivats
MXPA01008671A (es)	2002-03-14	2-aminopiridinas que contienen sustituyentes de tipo anillo condensado.
AU2017258665A1 (en)	2018-10-11	Process for the preparation of herbicidal compounds
JP4865559B2 (ja)	2012-02-01	鎮痛活性を有するインダゾール
AU769233B2 (en)	2004-01-22	2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
OA11557A (en)	2004-05-24	2-Aminopyridines containing fused ring substituents as nitric oxide synthase inhibitors.
MXPA99007398A (en)	2000-07-01	2-amino-6-(2-substituted-4-phenoxy)-substituted-pyridines
WO2003030993A1 (en)	2003-04-17	2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
EP2396335A1 (de)	2011-12-21	N[(6-azabicyclo[3.2.1]oct-1-yl)arylmethyl] benzamidderivate, deren herstellung und deren therapeutische verwendung
EA044101B1 (ru)	2023-07-24	Циклоолефиновые замещённые гетероароматические соединения и их применение